PDCD1 and neoplasm: To investigate the potential clinical efficacy of PTS in immunotherapy, we examined the distribution of checkpoint-related genes (LAG3, HAVCR2, PDCD1LG1, IDO1, TIGIT, PDCD1, PD-L1, and CTLA-4) and tumor mutation burden (TMB) in different PTS subgroups and found that LAG3, PDCD1LG1, IDO1, TIGIT, PDCD1, PD-L1, and CTLA-4 were upregulated in patients with low risk in the TCGA training set (Supplementary Figure S4A), while TMB was higher in patients with high risk (Supplementary Figure S4B).